AI·News & analysis
Isomorphic Labs raises $5 billion to put AI-designed drugs into trials
Demis Hassabis's AI drug company closed a $5 billion Series C, six months after a $2.1 billion round, and says it is heading toward its first clinical trials.

Tide
Ripple
Sci-fi
9/10
Reality
Lab
An AI that designs medicine molecules before lunch.How we rate
Isomorphic Labs, the Google DeepMind spinout that uses AI to design drugs, raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital.
Every existing investor, including Alphabet, joined, and the round followed a $2.1 billion raise in May. The money pays for its drug-design engine and for the work needed to reach clinical trials. No AI-designed drug has been approved yet, and more news is due in 2027.
What to know
- Isomorphic Labs announced a $5 billion Series C on November 17, 2026, co-led by Greenoaks and Sequoia Capital.
- It comes six months after a $2.1 billion Series B in May, and every existing investor took part again.
- The money funds its drug-design engine, IsoDDE, and the work needed to start clinical trials.
- The company did not disclose its valuation. An earlier report put it near $50 billion.
Isomorphic Labs announced a $5 billion Series C on Tuesday, co-led by Greenoaks and Sequoia Capital. That is a huge check for a company that has not yet put a medicine into a person. So what are investors buying?
What did Isomorphic announce?
The company raised $5 billion in a Series C. A Series C is a later round of startup funding, where investors buy a share of the company after earlier rounds already happened.
Andreessen Horowitz and several other new investors joined the two leads. Alphabet, Google's parent company, made what Isomorphic calls a continued significant investment.
Every existing backer came back too: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The round was oversubscribed, which means more investors wanted in than there was room for.
Who is Isomorphic Labs?
Isomorphic started in 2021 as a spinout from Google DeepMind, Google's AI research lab. Its job is to design new medicines with AI.
It is based in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland. Demis Hassabis is its founder and CEO.
Hassabis and John Jumper won the Nobel Prize in chemistry for AlphaFold. AlphaFold is an AI system that predicts the 3D shape of a protein from nothing but its genetic code. Isomorphic builds on that work.
First, what is a drug-design engine?
Designing a drug is a bit like searching for a key that fits a very odd lock. The lock is a protein in the body that is involved in a disease. The key is a molecule that can switch it on or off.
Isomorphic's engine is called IsoDDE. It is a group of AI simulation models, each exploring a different area of chemistry. Together they design and refine molecules that have drug-like properties.
The company also uses its own AI agents. An AI agent is a program that works through a task step by step on its own, and here it reasons about complex biology.
In real life A traditional lab might make and test thousands of molecules by hand to find a good one. A design engine tries to do much of that guessing on a computer first, so the lab only builds the best candidates.
How much money has it raised so far?
The new round is the third big one in about 18 months. Thrive Capital led the first two.
- March 2025: $600 million, the first outside round.
- May 2026: $2.1 billion Series B, announced on May 12.
- November 2026: $5 billion Series C.
Together, that adds up to $7.7 billion. The Series C arrived only six months after the Series B.
The big picture: few private companies in any field raise that much that fast. For a company with no approved product, it is rare.
What will the money pay for?
Isomorphic says the money will fund three things. The first is more work on IsoDDE. The second is moving into new areas of biology with more advanced AI models. The third is building the translational and clinical-development setup it needs to carry candidates toward patient testing.
A clinical trial is a study where a new medicine is tested in people. It comes after preclinical work, which means tests in the lab and in animals. Isomorphic says it has positive preclinical results in cancer and immune-system programs, both its own and with partners.
The company is also creating what it calls a partner ecosystem, to better understand how diseases work at the molecular level.
Which drug makers are already on board?
Isomorphic has deals with three big pharmaceutical companies.
- Eli Lilly: small-molecule drugs against targets the companies have not named.
- Novartis: started in January 2024 on three hard targets, then expanded in February 2025 with up to three more research programs.
- Johnson & Johnson: several targets, spanning small molecules and biologics.
Small molecules are the classic pills: compact chemicals that slip into cells. Biologics are larger, more complex medicines, such as antibodies.
Hassabis told Bloomberg that the company has more than 20 programs underway. He also said it wants to expand into "pretty much all modalities," meaning every type of medicine, including biologics.
Why do investors think it can scale?
Hassabis told Bloomberg: "What we're trying to build is a platform to do hundreds of drugs a year." That is a very different pace from the old model, where a company might spend years on a single candidate.
Konstantine Buhler, a partner at Sequoia, told Bloomberg that his firm backed Isomorphic because it has found scaling laws for its models. Scaling laws mean the AI keeps getting better when you give it more computing power and more data.
Hassabis also said the company has very secure compute pipelines. In plain words, he is confident it can get the chips it needs.
Max Jaderberg, the company's president, said its teams make repeatable scientific advances every week. He said those turn into better molecules with the potential to become new medicines.
When will the first trials start?
This is the part everyone is waiting for. In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026.
This time he did not give an updated target. He said the company is on track with its regulatory submissions, the paperwork regulators need before a trial can begin. He said there will be more to announce in 2027.
The catch: no regulator has approved an AI-designed drug yet. Good lab results do not always carry over to people, and that is the real test ahead.
Why does AlphaFold matter here?
Proteins do most of the work in your body, and their shape decides what they do. For decades, finding that shape for a single protein could take years of lab work.
AlphaFold changed that by predicting a protein's 3D structure from its genetic sequence alone. That earned Hassabis and Jumper the Nobel Prize in chemistry. Isomorphic took the idea one step further: instead of only reading the lock, it designs the key.
The company says its engine now generates molecules "with unprecedented precision and speed," in Hassabis's words. Those are claims from the company, and the clinical trials will be the first outside check.
What does "global infrastructure" mean?
Part of the money will go to global infrastructure for AI-led bioengineering, plus the translational and clinical-development setup mentioned above. Translational work is the bridge between a lab discovery and a test in people.
In plain words, building a good molecule is only half the job. The company also needs the people, partners and processes to test it safely and file it with regulators.
What about the valuation?
Isomorphic did not say what the round values the company at. A report earlier this month, before the announcement, said the company was looking to raise at a valuation of about $50 billion.
That figure is a report, not a confirmed number, so treat it as unverified until the company says otherwise.
What changed for Hassabis?
This is the first Isomorphic round since Hassabis stepped back as Google DeepMind's chief executive in August. He now chairs DeepMind and is Alphabet's chief scientist, and he is still the CEO of Isomorphic.
That puts one person at the center of both the research lab that built AlphaFold and the company trying to turn it into medicine. The funding vote suggests investors like that link.
What it means for you
- Not a pill yet: nothing from Isomorphic is available to patients, and no trial has been announced.
- Watch 2027: the company says its next news on trials and regulatory steps comes next year.
- Bigger picture: if AI-designed molecules do reach trials, the way new medicines are found could speed up over time.
- Be patient: even a fast start takes years of testing before any medicine reaches a pharmacy.
The bottom line
Isomorphic Labs now has $5 billion to prove that AI can design medicines, not just predict protein shapes. Investors, including Alphabet, clearly believe it. The proof will come when its first candidates meet real patients.
Key facts
- Round
- $5 billion Series C
- Co-leads
- Greenoaks and Sequoia Capital
- Previous round
- $2.1 billion Series B (May 2026)
- Drug-design engine
- IsoDDE
- Pharma partners
- Eli Lilly, Novartis, Johnson & Johnson
Got questions?
Quick answers, plain wordsHow much did Isomorphic Labs raise?
It raised $5 billion in a Series C round, announced on November 17, 2026. The round was co-led by Greenoaks and Sequoia Capital.
What is Isomorphic Labs?
It is an AI drug-design company that Google DeepMind spun out in 2021. It builds on AlphaFold, the DeepMind system that predicts the 3D shape of proteins.
Who runs Isomorphic Labs?
Demis Hassabis is the founder and CEO. He also shared a Nobel Prize in chemistry for the AlphaFold work and is now chair of Google DeepMind.
What is IsoDDE?
It is the company's drug-design engine. It is a group of AI simulation models that explore chemistry to design and improve molecules that could become medicines.
What is a Series C round?
It is a later stage of venture funding, after a startup has raised earlier rounds such as Series A and B. Investors put in money for a share of the company.
Has an AI-designed drug been approved yet?
No. No regulator has approved an AI-designed drug so far. Isomorphic's candidates have not entered human trials yet.
When will Isomorphic's first clinical trials start?
In January, Hassabis said the company expected first trials by the end of 2026. He did not give an updated date now and said there will be more to announce in 2027.
Which drug companies work with Isomorphic?
Eli Lilly, Novartis and Johnson & Johnson all have partnerships with it. Novartis began in January 2024 and expanded the work in February 2025.
What is Isomorphic's valuation?
The company did not say. A report earlier this month put it at about $50 billion, but the company has not confirmed that figure.
SourcesIsomorphic Labs
Topics and tagsGoogle, Funding & deals, isomorphic labs, drug discovery
Go deeper
Related stories

Blue J raises $176 million to put AI agents to work on tax returns and IRS letters
The Toronto startup is now valued at more than $700 million. It will spend the money on Workflows, AI agents that do tax work, and on a push into the UK.

LangChain raises $300 million at a $3 billion valuation for AI agents
The AI agent software company more than doubled its value in a year, and says 7,000 organizations now use its LangSmith platform.

Valon raises $150 million to put AI agents to work on 1 in 6 US mortgages
The mortgage software startup doubled its valuation to $2.3 billion. Its ValonOS platform and AI agents are now under contract to run one in six outstanding US mortgages.
More in brief
- ASELSAN's EJDERHA electromagnetic weapon disables 51 drones with one commandNov 21
- Microsoft To Do will shut down on June 30, 2027Nov 21
- Medtronic's Hugo surgical robot cleared for general surgery in the USNov 21
- Google's Gemini now turns noisy fire radio into text for Watch DutyNov 21
- Internet Archive staff move to unionize with CWANov 20
- Etsy sellers are leaving over new terms that allow AI trainingNov 20